Compare Stocks: PBH, CRNX, ALKS, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.06 -0.8%	$49.98	$25.17 ▼ $55.67	$8.23B	0.34	1.71 million shs	1.27 million shs
CRNX Crinetics Pharmaceuticals	$84.70 +0.3%	$63.99	$28.73 ▼ $84.71	$8.98B	0.12	2.77 million shs	2.28 million shs
LQDA Liquidia	$74.44 +3.2%	$78.67	$21.15 ▼ $93.61	$6.66B	0.58	1.63 million shs	2.52 million shs
PBH Prestige Consumer Healthcare	$51.51 +0.4%	$49.46	$42.62 ▼ $71.07	$2.43B	0.34	580,235 shs	487,058 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-0.22%	-5.54%	+30.90%	+71.36%
CRNX Crinetics Pharmaceuticals	0.00%	+0.74%	+0.94%	+130.35%	+181.49%
LQDA Liquidia	0.00%	-17.49%	-1.10%	+30.76%	+195.40%
PBH Prestige Consumer Healthcare	0.00%	-6.22%	+1.75%	+10.32%	-22.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.06 -0.8%	$49.98	$25.17 ▼ $55.67	$8.23B	0.34	1.71 million shs	1.27 million shs
CRNX Crinetics Pharmaceuticals	$84.70 +0.3%	$63.99	$28.73 ▼ $84.71	$8.98B	0.12	2.77 million shs	2.28 million shs
LQDA Liquidia	$74.44 +3.2%	$78.67	$21.15 ▼ $93.61	$6.66B	0.58	1.63 million shs	2.52 million shs
PBH Prestige Consumer Healthcare	$51.51 +0.4%	$49.46	$42.62 ▼ $71.07	$2.43B	0.34	580,235 shs	487,058 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-0.22%	-5.54%	+30.90%	+71.36%
CRNX Crinetics Pharmaceuticals	0.00%	+0.74%	+0.94%	+130.35%	+181.49%
LQDA Liquidia	0.00%	-17.49%	-1.10%	+30.76%	+195.40%
PBH Prestige Consumer Healthcare	0.00%	-6.22%	+1.75%	+10.32%	-22.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	11.22% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.37% Downside
LQDA Liquidia	2.45	Hold	$98.08	31.76% Upside
PBH Prestige Consumer Healthcare	2.17	Hold	$70.75	37.36% Upside

Current Analyst Ratings Breakdown

Latest PBH, CRNX, ALKS, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	LQDA Liquidia	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$79.00 ➝ $92.00
8/12/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$109.00 ➝ $111.00
8/12/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $110.00
8/12/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Hold	$90.00
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/30/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	ALKS Alkermes	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$60.00 ➝ $61.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.94	$1.67 per share	29.30	$10.78 per share	4.55
CRNX Crinetics Pharmaceuticals	$7.70M	1,166.77	N/A	N/A	$11.24 per share	7.54
LQDA Liquidia	$158.32M	42.09	N/A	N/A	$2.18 per share	34.15
PBH Prestige Consumer Healthcare	$1.10B	2.21	$5.22 per share	9.87	$40.46 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	129.11	204.42	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	N/A
LQDA Liquidia	-$68.92M	$1.37	54.34	17.00	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	14.43	10.08	1.61	15.57%	11.39%	5.66%	N/A

Latest PBH, CRNX, ALKS, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	3.69%	N/A	53.22%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LQDA Liquidia	0.63	2.31	2.03
PBH Prestige Consumer Healthcare	1.06	3.23	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
CRNX Crinetics Pharmaceuticals	98.51%
LQDA Liquidia	64.54%
PBH Prestige Consumer Healthcare	99.95%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
CRNX Crinetics Pharmaceuticals	3.80%
LQDA Liquidia	25.60%
PBH Prestige Consumer Healthcare	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable
PBH Prestige Consumer Healthcare	540	47.38 million	46.66 million	Optionable

PBH, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

Prestige Consumer Healthcare Announces Operations Leadership Transition

August 14 at 5:11 PM | tipranks.com

Here's why Prestige Consumer Healthcare (PBH) is a strong value stock

August 14 at 1:25 PM | msn.com

Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript

August 13 at 10:23 PM | finance.yahoo.com

PBH or SYK: Which Is the Better Value Stock Right Now?

August 12, 2026 | zacks.com

Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to "Hold" Rating

August 12, 2026 | marketbeat.com

Prestige Consumer Healthcare Inc.

August 12, 2026 | barrons.com

Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference

August 12, 2026 | markets.businessinsider.com

Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH

August 11, 2026 | marketbeat.com

Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

August 11, 2026 | marketbeat.com

Prestige Consumer Healthcare (PBH) Is Up 9.2% After Raising 2027 Outlook On Recent Acquisitions

August 8, 2026 | finance.yahoo.com

Prestige Consumer Healthcare Q1 Earnings Call Highlights

August 8, 2026 | marketbeat.com

Prestige Consumer Healthcare (NYSE:PBH) Issues Earnings Results, Beats Expectations By $0.09 EPS

August 8, 2026 | marketbeat.com

Prestige Consumer Healthcare Inc. $PBH Shares Bought by First Trust Advisors LP

August 8, 2026 | marketbeat.com

PBH stock up on Q1 earnings and revenue beat, fiscal '27 view raised

August 7, 2026 | msn.com

Prestige Consumer Healthcare Inc. 2027 Q1 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot

August 6, 2026 | wtop.comW

Prestige Consumer Healthcare (PBH) Q1 Earnings and Revenues Surpass Estimates

August 6, 2026 | zacks.com

Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2027 Earnings Guidance

August 6, 2026 | marketbeat.com

Prestige Consumer Healthcare Reports Q1 Fiscal 2027 Results, Raises Full-Year Outlook on Breathe Right and LaCorium Acquisitions

August 6, 2026 | quiverquant.comQ

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results

August 6, 2026 | globenewswire.com

Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $70.75

August 6, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PBH, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

$49.06 -0.39 (-0.79%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$51.23 +2.17 (+4.43%)

As of 08/14/2026 07:58 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.70 +0.26 (+0.31%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$84.68 -0.02 (-0.03%)

As of 08/14/2026 07:34 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Liquidia NASDAQ:LQDA

$74.44 +2.34 (+3.25%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.33 +1.89 (+2.53%)

As of 08/14/2026 07:55 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Prestige Consumer Healthcare NYSE:PBH

$51.51 +0.19 (+0.36%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$51.38 -0.12 (-0.24%)

As of 08/14/2026 07:34 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, CRNX, ALKS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, CRNX, ALKS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PBH, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, CRNX, ALKS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, CRNX, ALKS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PBH, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools